ReviewCerebral circulation - cognition and behavior2026
Vascular cognitive impairment in China: Epidemiology, risk factors, healthcare system, management challenges, therapeutic modalities, and prevention strategies.
Review in Cerebral circulation - cognition and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular cognitive impairment (VCI) is an increasingly important contributor to cognitive decline in China, where rapid population aging intersects with a substantial burden of stroke, cerebral small vessel disease, and cardiometabolic risk. This narrative review synthesizes Chinese epidemiological, clinical, health-services, and policy literature on VCI, supplemented by key international consensus and interventional evidence when directly relevant. Available evidence indicates that the vascular contribution to cognitive disorders in China is substantial but heterogeneously measured because of differences in case definition, screening tools, study setting, and follow-up design. Post-stroke cognitive impairment is especially important because it is common, clinically recognizable, and reachable through existing stroke follow-up pathways. Across studies, hypertension and cardiometabolic multimorbidity emerge as the most actionable modifiable drivers. China has strengthened its policy response through updated clinical guidance and a national dementia action plan, yet implementation remains constrained by inconsistent screening, uneven specialist capacity, fragmented referral pathways, and limited longitudinal follow-up. Therapeutically, direct evidence for interventions targeting established VCI syndromes remains limited. The strongest available support is indirect and comes from vascular risk reduction, particularly blood pressure lowering for broader dementia or cognitive decline endpoints, while multidomain and symptomatic interventions show phenotype-specific but more heterogeneous signals. A practical China-adapted response is therefore a tiered life-course model linking chronic disease management, post-stroke surveillance, specialist diagnosis, multidomain intervention, and caregiver support. Future priorities include harmonized diagnostics, clearer evidence characterization, biomarker-enabled longitudinal cohorts, and pragmatic implementation-science studies focused on adaptation, cost, and sustainability in community and rural settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.